Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to β-Amyloid Peptide42
Author(s) -
Alessia Maddalena,
Andreas Papassotiropoulos,
Britta Müller-Tillmanns,
Hans H. Jung,
Thomas Hegi,
Roger M. Nitsch,
Christoph Höck
Publication year - 2003
Publication title -
archives of neurology
Language(s) - English
Resource type - Journals
eISSN - 1538-3687
pISSN - 0003-9942
DOI - 10.1001/archneur.60.9.1202
Subject(s) - cerebrospinal fluid , dementia , medicine , diagnostic accuracy , tau protein , alzheimer's disease , pathology , disease , gastroenterology
The antemortem diagnosis of Alzheimer disease (AD) requires time-consuming and costly procedures. Therefore, biochemical tests that can direct the physician rapidly to the correct diagnosis are highly desirable. Measurement of single biochemical markers in cerebrospinal fluid (CSF), such as total tau protein and beta-amyloid peptide42 (Abeta42), shows robust alterations that highly correlate with the clinical diagnosis of AD but generally lack sufficient diagnostic accuracy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom